Sympathoneural and adrenomedullary functional effects of α2c-adrenoreceptor gene polymorphism in healthy humans

被引:69
作者
Neumeister, A
Charney, DS
Belfer, I
Geraci, M
Holmes, C
Sharabi, Y
Alim, T
Bonne, O
Luckenbaugh, DA
Manji, H
Goldman, D
Goldstein, DS
机构
[1] Yale Univ, Sch Med, Dept Psychiat, Clin Neurosci Div,VA Connecticut Healthcare Syst, West Haven, CT 06516 USA
[2] NIMH, Mood & Anxiety Disorders Program, Sect Expt Therapeut & Pathophysiol, NIH, Bethesda, MD 20892 USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA
[5] NINDS, Clin Neurocardiol Sect, NIH, Bethesda, MD 20892 USA
[6] Chaim Sheba Med Ctr, Dept Med, IL-52621 Tel Hashomer, Israel
[7] Howard Univ, Coll Med, Dept Psychiat, Washington, DC USA
[8] NIMH, Mol Pathophysiol Lab, Bethesda, MD 20892 USA
[9] NIDCR, Pain & Neurosensory Mechanisms Branch, Bethesda, MD USA
关键词
alpha(2)-adrenoceptor; genetic variant; noradrenaline and adrenaline spillover; yohimbine;
D O I
10.1097/01213011-200503000-00002
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives alpha(2)-Adrenoreceptors restrain sympathetic nervous outflows and inhibit release of noradrenaline from sympathetic nerves. In-frame deletion of the alpha(2C)-adrenoreceptor subtype (alpha(2C)Del322-325) increases the risk of congestive heart failure. Increased delivery of catecholamines to cardiovascular receptors might explain this increased risk. Methods Twenty-nine healthy African-Americans genotyped for alpha(2)-adrenoreceptor subtype polymorphisms underwent H-3-noradrenaline and H-3-adrenaline intravenous infusion and arterial blood sampling for measurements of rates of entry of endogenous noradrenaline and adrenaline into arterial plasma (total body spillovers) by the tracer dilution technique. Eleven subjects were homozygotes for the alpha(2C)Del322-325 polymorphism, nine heterozygotes, and nine non-carriers. Subjects were studied during supine rest and during and after i.v. infusion of the alpha(2)-adrenoreceptor antagonist, yohimbine. Results At rest, homozygotes for the alpha(2C)Del322-325 polymorphism had higher total body noradrenaline spillover than did heterozygotes (t = 2.90, df = 18, P = 0.023) or non-carriers (t = 3.22, df = 18, P = 0.010). Adrenaline spillover was higher in homozygotes than non-carriers (t = 2.61, df = 18, P = 0.045). Administration of yohimbine produced larger, more sustained increments in noradrenaline spillover, heart rate, and anxiety in homozygotes than in the other groups. Conclusion In healthy people, alpha(2C)Del322-325 polymorphism is associated with increased sympathetic nervous and adrenomedullary hormonal activities, both during supine rest and during pharmacologically evoked catecholamine release. Polymorphisms of the alpha(2C)-adrenoreceptor may help explain individual differences in predisposition to a variety of disorders of catecholaminergic function, such as cardiovascular disorders, depression or anxiety disorders. Pharmacogenetics and Genomics 15:143-149 (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 31 条
[1]  
[Anonymous], 1992, CLIN NEUROGENETICS B
[2]  
BLAXALL HS, 1991, J PHARMACOL EXP THER, V259, P323
[3]   SUBTYPES OF ALPHA-1-ADRENERGIC AND ALPHA-2-ADRENERGIC RECEPTORS [J].
BYLUND, DB .
FASEB JOURNAL, 1992, 6 (03) :832-839
[4]  
BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600
[5]   CATECHOLAMINE RECEPTORS ON LOCUS COERULEUS NEURONS - PHARMACOLOGICAL CHARACTERIZATION [J].
CEDARBAUM, JM ;
AGHAJANIAN, GK .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1977, 44 (04) :375-385
[6]  
Charney Dennis S, 2004, Sci STKE, V2004, pre5, DOI 10.1126/stke.2252004re5
[7]  
CHARNEY DS, 1987, AM J PSYCHIAT, V144, P1030
[8]   Identification, course, and treatment of depression after admission for a cardiac condition: Rationale and patient characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project [J].
Cheok, F ;
Schrader, G ;
Banham, D ;
Marker, J ;
Hordacre, AL .
AMERICAN HEART JOURNAL, 2003, 146 (06) :978-984
[9]   Psychometric properties of the Impact of Event Scale - Revised [J].
Creamer, M ;
Bell, R ;
Failla, S .
BEHAVIOUR RESEARCH AND THERAPY, 2003, 41 (12) :1489-1496
[10]  
EISENHOFER G, 1986, CLIN CHEM, V32, P2030